Lipid mediators in plasma of autism spectrum disorders

Lipids in Health and Disease

Volumn 11, Issue 1, 2012, Pages

  El Ansary, Afaf ^a,b,c   Al Ayadhi, Laila ^b,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Autism Research and Treatment Center   (Saudi Arabia)

Author keywords

Arachidonic acid; Autism; Inflammation; Isoprostane; Leukotrienes; Prostaglandins

Indexed keywords

8 ISOPROSTANE; LIPID; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; LEUKOTRIENE;

ARTICLE; AUTISM; BLOOD LEVEL; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIPID ANALYSIS; MALE; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRESCHOOL CHILD; SCHOOL CHILD; BLOOD; BRAIN; GENETICS; INFLAMMATION; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; SAUDI ARABIA;

BIOLOGICAL MARKERS; BRAIN; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DINOPROSTONE; HUMANS; INFLAMMATION; ISOPROSTANES; LEUKOTRIENES; LIPID METABOLISM; MALE; ROC CURVE; SAUDI ARABIA;

MLCS; MLOWN;

EID: 84869234283     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-160     Document Type: Article

References (55)

1. Centers for Disease Control and Prevention (CDC): Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ. 2009, 58 (10): 1-20.
2. Ozonoff S, Iosif AM, Baguio F: A prospective study of the emergence of early behavioral signs of autism. J Am Acad Child Adolesc Psychiatry. 2010, 49 (3): 256-266.
3. Ozonoff S, Heung K, Byrd R, Hansen R, Hertz-Picciotto I: The onset of autism: patterns of symptom emergence in the first years of life. Autism Res. 2008, 1 (6): 320-328. 10.1002/aur.53
4. Hussain J, Woolf AD, Sandel M, Shannon MW: Environmental evaluation of a child with developmental disability. Pediatr Clin North Am. 2007, 54 (1): 47-62. 10.1016/j.pcl.2006.11.004
5. Kalkbrenner AE, Daniels JL, Chen JC, Poole C, Emch M, Morrissey J: Perinatal exposure to hazardous air pollutants and autism spectrum disorders at age 8. Epidemiology. 2010, 21 (5): 631-641. 10.1097/EDE.0b013e3181e65d76
6. Lintas C, Sacco R, Persico AM: Genome-wide expression studies in autism spectrum disorder, Rett syndrome, and Down syndrome. Neurobiol Dis. 2012, 45 (1): 57-68. 10.1016/j.nbd.2010.11.010
7. El-Ansary AK, Ben Bacha AG, Al-Ayadhi LY: Proinflammatory and proapoptotic markers in relation to mono and di-cations in plasma of autistic patients from Saudi Arabia. J Neuroinflammation. 2011, 8: 142- 10.1186/1742-2094-8-142
8. El-Ansary AK, Ben Bacha AG, Al-Ayadhi LY: Relationship between chronic lead toxicity and plasma neurotransmitters in autistic patients from Saudi Arabia. Clin Biochem. 2011, 44 (13): 1116-1120. 10.1016/j.clinbiochem.2011.06.982
9. Rossignol DA, Frye RE: A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012, 17: 389-401. 10.1038/mp.2011.165
10. Schuhmann MU, Mokhtarzadeh M, Stichtenoth DO: Temporal profiles of cerebrospinal fluid leukotrienes, brain edema and inflammatory response following experimental brain injury. Neurol Res. 2003, 25 (5): 481-491. 10.1179/016164103101201896
11. Black KL, Hoff JT: Leukotrienes Increase Blood-brain Barrier Permeability Following Intraparenchymal Injections in Rats. Ann Neurol. 1985, 18 (3): 349-351. 10.1002/ana.410180313
12. Sang N, Chen C: Lipid signaling and synaptic plasticity. Neuroscientist. 2006, 12 (5): 425-434. 10.1177/1073858406290794
13. Chen C, Bazan NG: Lipid signaling: sleep, synaptic plasticity and neuroprotection. Prostaglandins Other Lipid Mediat. 2005, 77 (1-4): 65-76.
14. Hein AM, O'Banion MK: Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol. 2009, 40 (1): 15-32. 10.1007/s12035-009-8066-z
15. Leger DF: Prostaglandins E2 at new glance: Novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol. 2010, 42 (2): 198-201. 10.1016/j.biocel.2009.09.015
16. Roberts LJ, Morrow JD: Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000, 28: 505-513. 10.1016/S0891-5849(99)00264-6
17. Narumiya S, Ogorochi T, Nakao K, Hayaishi O: Prostaglandin D2 in the rat brain, spinal cord and the pituitary: basal level and regional distribution. Life Science. 1982, 31: 2093-2103. 10.1016/0024-3205(82)90101-1. 10.1016/0024-3205(82)90101-1
18. Brus R, Herman ZS, Szkilnik R, Zabawska J: Mediation of central prostaglandin effects by serotoninergic neurons. Psychopharmacology. 1979, 64: 116-120.
19. Saito R, Kamiya H, Ono N: Role of central muscarinic receptor of prostaglandin I2 in cardiovascular function in rat. Brain Res. 1985, 330: 167-169. 10.1016/0006-8993(85)90021-6
20. Naidu PS, Kulkarni SK: Differential effects of cyclooxygenase inhibitors on haloperidolinduced catalepsy. Prog Neuropsychopharmacol Biol Psychiatry. 2002, 26: 819-822. 10.1016/S0278-5846(01)00289-5
21. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ: A series of prostaglandin F2-like compounds are produced in vivo in humans by anon-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990, 87 (23): 9383-9387. 10.1073/pnas.87.23.9383
22. Hardy ARP, Chemtob S, Detbarn WD, Morrow JD: Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem. 1998, 273: 13605-13612. 10.1074/jbc.273.22.13605
23. Ito S, Okuda-Ashitaka E, Minami T: Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res. 2001, 41 (4): 299-332. 10.1016/S0168-0102(01)00289-9
24. Tamiji J, Crawford DA: The neurobiology of lipid metabolism in autism spectrum disorders. Neurosignals. 2010, 18 (2): 98-112. 10.1159/000323189
25. El-Ansary AK, Bacha AG, Al-Ayahdi LY: Impaired plasma phospholipids and relative amounts of essential polyunsaturated fatty acids in autistic patients from Saudi Arabia. Lipids Health Dis. 2011, 22: 10-63.
26. Pepe MS, Feng Z, Huang Y: Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol. 2008, 167 (3): 362-368.
27. Evans TA, Siedlak SA, Lu L: The autistic phenotype exhibits a remarkably localized modification of brain protein by products of free radical-induced lipid oxidation. Am J Biochem Biotechnol. 2008, 4: 61-72.
28. Salomon RG, Subbanagounder G, Singh U, O'Neil J, Hoff HF: Oxidation of low-density lipoproteins produces levuglandin-protein adducts. Chem Res Toxicol. 1997, 10 (7): 750-759. 10.1021/tx970016b
29. Boutaud O, Brame CJ, Salomon RG, Roberts LJ, Oates JA: Characterization of the lysyl adducts formed from prostaglandin H2 via the levuglandin pathway. Biochemistry. 1999, 38 (29): 9389-9396. 10.1021/bi990470+
30. Murthi KK, Friedman LR, Oleinick NL, Salomon RG: Formation of DNA-protein cross-links in mammalian cells by levuglandin E2. Biochemistry. 1993, 32 (15): 4090-4097. 10.1021/bi00066a034
31. Salomon RG: Levuglandins and isolevuglandins: stealthy toxins of oxidative injury. Antioxid. Redox. Signal. 2005, 7 (1-2): 185-201.
32. Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC: Increased excretion of lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids. 2005, 73 (5): 379-384. 10.1016/j.plefa.2005.06.002
33. El-Ansary A, Ben Bacha AG, Al-Ayahdi LY: Plasma fatty acids as diagnostic markers in autistic patients from Saudi Arabia. Lipids Health Dis. 2011, 10: 62- 10.1186/1476-511X-10-62
34. Wiest MM, German JB, Harvey DJ, Watkins SM, Hertz-Picciotto I: Plasma fatty acid profiles in autism: a case-control study. Prostaglandins Leukot Essent Fatty Acids. 2009, 80 (4): 221-227. 10.1016/j.plefa.2009.01.007
35. Lu L: Clinical and animal studies of lipid-derived protein modifications in autism, kidney dialysis, keratitis and age-related macular degeneration. PhD thesis, Department of Chemistry Department. 2007, Case Western Researve University
36. Singh VK: Phenotypic expression of autoimmune autistic disorder (AAD): a major subset of autism. Ann Clin Psychiatry. 2009, 21 (3): 148-161.
37. Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK: Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr. 1999, 134: 607-613. 10.1016/S0022-3476(99)70248-9
38. Vojdani A, Campbell AW, Anyanwu E, Kashanian A, Bock K, Vojdani E: Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol. 2002, 129 (1-2): 168-177.
39. Steinke JW, Kennedy JL: Leukotriene Inhibitors in Sinusitis. Curr Infect Dis Rep. 2012, In press
40. Wu Y, He C, Gao Y, He S, Liu Y, Lai L: Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors. J Med Chem. 2012, 55 (6): 2597-2605. 10.1021/jm201497k
41. Muskiet FAJ: Pathophysiology and Evolutionary Aspects of Dietary Fats and Long-Chain Polyunsaturated Fatty Acids across the Life Cycle. Fat Detection: Taste, Texture, and Post Ingestive Effects. Boca Raton (FL). Edited by: Montmayeur JP, Le C. 2010, Chapter 2. Frontiers in Neuroscience, CRC Press
42. Abu Shmais GA, Al-Aydhi L, Al-Dbass A, El-Ansary A: Mechanism of nitrogen metabolism-related parameters and enzyme activities in the pathophysiology of autism. J Neurodev Disord. 2012, 10.1186/1866-1955-4-4.
43. Baron-Cohen S, Ring R: The amygdale theory of autism. Neurosci Biobehav Rev. 2000, 24 (3): 355-364. 10.1016/S0149-7634(00)00011-7
44. Lozinsky S: Master thesis. Misoprostol elevates intracellular calcium levels and increases glutamate release in type-I astrocytes: Implication in autism. 2010, Toronto Ontario: York University
45. Libbey JE, Sweeten TL, McMahon WM, Fujinami RS: Autistic disorder and viral infections. J Neurovirol. 2005, 11 (1): 1-10. 10.1080/13550280590900553
46. Manzardo AM, Henkhaus R, Dhillon S, Butler MG: Plasma cytokine levels in children with autistic disorder and unrelated siblings. Int J Dev Neurosci. 2012, 30 (2): 121-127. 10.1016/j.ijdevneu.2011.12.003
47. Wei H, Chadman KK, McCloskey DP, Sheikh AM, Malik M, Brown WT, Li X: Brain IL-6 elevation causes neuronal circuitry imbalances and mediates autism-like behaviors. Biochim Biophys Acta. 2012, 1822 (6): 831-842. 10.1016/j.bbadis.2012.01.011
48. Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT, Li X: IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J Neuroinflammation. 2011, 8: 52- 10.1186/1742-2094-8-52
49. Auyeung B, Baron-Cohen S, Ashwin E, Knickmeyer R, Taylor K, Hackett G: Fetal testosterone and autistic traits. Brit J Psychol (London, England. 1953, 100 (1): 1-22.
50. James WH: Further evidence that some male-based neurodevelopmental disorders are associated with high intrauterine testosterone concentrations. Dev Med Child Neurol. 2008, 50 (1): 15-18. 10.1111/j.1469-8749.2007.02001.x
51. Geier D, Geier M: A clinical trial of combined anti-androgenand anti-heavy metal therapy in autistic disorders. Neuro Endocrinol Lett. 2006, 27 (6): 833-838.
52. Geier D, Geier M: A prospective assessment of androgen levels in patients with autistic spectrum disorders: biochemical underpinnings and suggested therapies. Neuro Endocrinol Lett. 2007, 28 (5): 565-573.
53. Tordjman S, Ferrari P, Sulmont V, Duyme M, Roubertoux P: Androgenic activity in autism. Am J Psychiatry. 1997, 154: 1626-1627.
54. Dean S: Regulation of cerebellar estradiol synthesis and Purkinje cell morphology by prostaglandins: Implications for neurodevelopmental disease. 2009, Baltimore: University of Maryland
55. Rangel-Huerta OD, Aguilera CM, Mesa MD, Gil A: Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials. Br J Nutr. 2012, 107 (2): S159-S170. 10.1017/S0007114512001559